Allurion Technologies has announced the company’s entry into Asia with the launch of the Elipse Program in Hong Kong, Malaysia, and Singapore. Building upon its success in Europe, Middle East, and Latin America, the company’s entry into Asia could impact the lives of over one billion people who are overweight or have obesity in a region that historically has had limited access to non-invasive weight loss treatments. According to a study released by the Asian Development Bank Institute, over 40% of adults in Asia are overweight or obese, an increase of close to 20% in just the past 20 years.
"With the launch of our weight loss program in Asia, our company enters its next phase of rapid expansion,” said Allurion co-founder and Chief Executive Officer, Dr Shantanu Gaur. “Obesity has been on the rise in Asia for decades, but truly frictionless treatment options have been absent. We intend to change that.”
Allurion has already treated over 25,000 individuals in over 30 countries around the world with its 360-degree Allurion weight loss programme. Allurion’s weight loss programme features the Elipse Balloon - the world’s first and only procedureless medical device for weight loss. According to the company, unlike other weight loss balloons on the market the Elipse Balloon is designed to be placed and removed without surgery, endoscopy or anaesthesia. It is swallowed in a capsule during an outpatient office visit and is designed to remain in the stomach for approximately four months, after which it opens and passes naturally from the body.
"The arrival of the Elipse Balloon in Gleneagles Hospital Penang was a historical moment for all of us involved,” said Dr Kirubakaran Malapan of Gleneagles Hospital Penang. “I am very confident that this will be an appealing treatment option in our fight against obesity.”
Allurion has also announced the addition of John Liljequist as the Director of Asia Pacific Sales. Mr Liljequist has over 18 years of commercial medical device experience in the Asia Pacific region. Most recently he served as Senior Commercial Director at Establishment Labs and was responsible for driving sales, strategy and commercial activities across Japan, Korea, Hong Kong, Australia, and China. Prior to Establishment Labs, Mr Liljequist managed the breast implant franchise at Allergan and was the integration lead for Coolsculpting across APAC, India, Middle East, and Africa.
“I am delighted to have John join the Allurion commercial team,” said Benoit Chardon, Allurion Executive Vice President of Global Commercial. “He is a joining at a time of substantial growth and will have an opportunity to deploy his talent, experience, and passion in one of the fastest growing weight loss markets in the world.”